IP Library Granted Patent US 7,902,156
Granted Patent B2
US 7,902,156 · App. 11/884,629 · Granted Mar 8, 2011

Aprotinin polypeptides for transporting a compound across the blood-brain barrier

Assignee: Angiochem Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,902,156
App. No.
11/884,629
Granted
Mar 8, 2011
Kind
B2
Abstract

The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates. The present invention also relates to the use of these polypeptide for transporting a compound or drug across the blood-brain barrier of a mammal and in the treatment and diagnosis of neurological diseases.

Claims (16)

1. A polypeptide comprising an amino acid sequence having at least 80% identity to the sequence of Angiopep-1 (SEQ ID NO.:67), wherein said polypeptide has a substitution at the position corresponding to the cysteine at position 7 of the Angiopep-1 sequence, or a pharmaceutically acceptable salt thereof.

2. The polypeptide of claim 1 , wherein said substitution is a serine substitution.

3. The polypeptide of claim 1 , wherein said polypeptide is capable of crossing the blood-brain barrier or an in vitro model thereof.

4. The polypeptide of claim 1 , where said percent identity is at least 85%.

5. The polypeptide of claim 4 , wherein said percent identity is at least 90%.

6. The polypeptide of claim 2 comprising the sequence of Angiopep-2 (SEQ ID NO.:97).

7. The polypeptide of claim 1 , wherein said polypeptide is a fusion protein.

8. The fusion protein of claim 7 comprising leptin.

9. A conjugate comprising:

(a) the polypeptide of claim 1 ; and

(b) a peptide or protein, wherein said peptide or said protein is conjugated to said polypeptide.

10. The conjugate of claim 9 , wherein said protein comprises leptin.

11. A composition comprising the polypeptide of claim 1 .

12. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

13. A method of treating a patient suffering from obesity, said method comprising administering to said patient a polypeptide of claim 8 in an effective amount.

14. A method of treating a patient suffering from obesity, said method comprising administering to said patient a conjugate of claim 10 in an effective amount.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Sep 27, 2021
From: MMV FINANCIAL INC.
To: ANGIOCHEM INC.
Reel/Frame 057607/0994 →
SECURITY AGREEMENT Recorded May 9, 2008
From: ANGIOCHEM INC.
To: MMV FINANCIAL INC.
Reel/Frame 020929/0129 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2008
From: UNIVERSITE DU QUEBEC A MONTREAL
To: TRANSFERT PLUS, S.E.C.
Reel/Frame 020771/0464 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2008
From: BELIVEAU, RICHARD; DEMEULE, MICHEL; CHE, CHRISTIAN; REGINA, ANTHONY
To: UNIVERSITE DU QUEBEC A MONTREAL
Reel/Frame 020771/0531 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2008
From: TRANSFERT PLUS, S.E.C.
To: ANGIOCHEM, INC.
Reel/Frame 020771/0602 →
Continuity (2)
Provisional Application 60653928 · Feb 18, 2005
Related Publication 20080299039A1 · Dec 4, 2008